Dr Reddy's Lab launches prostate cancer drug in India
New Delhi: Drug firm Dr Reddy's Laboratories Friday said it has launched a cancer drug 'Pamorelin LA' in the country under an agreement with Switzerland-based Debiopharm Group.
The Hyderabad-based firm has launched Pamorelin LA in India on December 3, 2012, under an exclusive marketing and sales agreement with Debiopharm Group, Switzerland, Dr Reddy's Laboratories said in a statement.
Pamorelin LA is used for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer, it added.
"Pamorelin LA will be imported in bulk from Debio Recherche Pharmaceutique. It will be made available primarily to urologists and oncologists across India," Dr Reddy's said.
The company's scrip closed at Rs 1,837.10 on the BSE, down 0.56 percent from its previous close.